Prognostic value of residual disease biology and gene expression changes during the neoadjuvant treatment in HER2-positive early-breast cancer.



- Citation:
- Cancer Research vol 84 (9_Supplement) :PO2-01-06-PO2-01-06
- Meeting Instance:
- SABCS 2023
- Year:
- 2024
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Meta-Analysis
- Data Sharing:
- Alliance-data-source,-external-user
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 4425